Cardamonin

Manufactured by Bio-Techne

Sourced in United States, United Kingdom

Cardamonin is a naturally occurring compound that can be used as a research tool in laboratory settings. It is extracted from various plant sources and exhibits certain biochemical properties that may be of interest to researchers working in relevant fields. The core function of Cardamonin is to serve as a chemical compound for investigational purposes, without any specific interpretation or extrapolation on its intended use.

Automatically generated - may contain errors

Lab products found in correlation

Bovine serum albumin (bsa), by Merck Group (2 mentions) Insulin, by Merck Group (2 mentions) Hepes, by Merck Group (2 mentions) Hydrocortisone, by Merck Group (2 mentions) Doxorubicin hydrochloride, by Merck Group (2 mentions) Paclitaxel, by Merck Group (2 mentions) 5 fluorouracil, by Merck Group (2 mentions) Cama 1, by American Type Culture Collection (2 mentions) Yap inhibitor vp, by Merck Group (1 mentions) Palmitate, by Merck Group (1 mentions) Aicar, by Bio-Techne (1 mentions) Costunolide, by Bio-Techne (1 mentions) Pictilisib, by Selleck Chemicals (1 mentions) Luteolin, by Selleck Chemicals (1 mentions) Tnf α, by Thermo Fisher Scientific (1 mentions) Bay11 7085, by Selleck Chemicals (1 mentions) Tpca 1, by Selleck Chemicals (1 mentions) Ikk 16, by Selleck Chemicals (1 mentions) Cid2858522, by Bio-Techne (1 mentions) Cgs 21680 hcl, by Bio-Techne (1 mentions)

8 protocols using cardamonin

Modulating Stem Cell Fate with YAP and β-Catenin Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

hESCs were seeded at a density of 10⁴ cells in Matrigel-coated eight-chamber slides, and after 3 days of culture, 0.5 µM of YAP inhibitor VP (Sigma) was added to the media for further culture of 24 h. The β-catenin inhibitor cardamonin (2 µM; Tocris) was added after 2 days of culture for further culture of 48 h. Cells were fixed in 4% formaldehyde/PBS at room temperature for 10 min and washed 3x with PBS before immunostaining and imaging.
For hNPC induction, hESCs were seeded according to the neural differentiation protocol described above and the β-catenin inhibitor cardamonin (0.5 µM; Tocris) was added in the fresh media daily from day 1 to day 10. The YAP inhibitor VP (0.5 µM; Sigma) was added in two 24 h pulses (days 5 and 9) to reduce toxicity effects.

Junqueira Alves C., Dariolli R., Haydak J., Kang S., Hannah T., Wiener R.J., DeFronzo S., Tejero R., Gusella G.L., Ramakrishnan A., Alves Dias R., Wojcinski A., Kesari S., Shen L., Sobie E.A., Rodrigues Furtado de Mendonça J.P., Azeloglu E.U., Zou H, & Friedel R.H. (2021). Plexin-B2 orchestrates collective stem cell dynamics via actomyosin contractility, cytoskeletal tension and adhesion. Nature Communications, 12, 6019.

+ Open protocol

+ Expand

Fatty Acid and Pharmacological Treatments

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Palmitate (Sigma) and DHA (Nu-Chek-Prep, Inc.) were dissolved in ethanol and then diluted (1:5.4 ratio) with 10% BSA (fatty acid-free and low endotoxin) diluted in 0.1 M phosphate-buffered saline (PBS). Palmitate and DHA treatment in these studies was based on physiological concentrations that have been previously observed in vivo or used for in vitro studies (Ajuwon and Spurlock, 2005 (link), Han et al., 2010 (link), Puri et al., 2009 (link), Weldon et al., 2007 (link)). Controls for fatty acid treatment contained BSA diluted in PBS with an equivalent ratio of ethanol.
AICAR (Tocris) or cardamonin (Tocris) were dissolved in DMSO and then diluted 1:400 and 1:10000 in culture medium to achieve final concentrations of 500 μM or 5 μM, respectively. Vehicle controls for AICAR and cardamonin treatment consisted of cultures in which an equivalent amount of DMSO was added to the medium.

Kim S.M., Neuendorff N., Chapkin R.S, & Earnest D.J. (2016). Role of Inflammatory Signaling in the Differential Effects of Saturated and Poly-unsaturated Fatty Acids on Peripheral Circadian Clocks. EBioMedicine, 7, 100-111.

+ Open protocol

+ Expand

Hantavirus Infection of Umbilical Vein Endothelial Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cords as previously described [26] (link) and cultured in Endothelial Cell Medium (San Diego, CA), containing essential and non-essential amino acids, vitamins, organic and inorganic compounds, hormones, growth factors, trace minerals, and a low concentration of fetal bovine serum (FBS) (5%) at 37°C in humidified air containing 5% CO₂. The cells were used at fewer than 8 passages in this study.
HTNV, strain 76–118 [27] (link), was proliferated in Vero E6 cells and titered using an immunofluorescence staining assay for HTNV nucleocapsid protein as previously described [28] . The TCID₅₀ was 10^5.5/ml and calculated using the Reed-Muench method.
During all experiments, the cells were pretreated with 30 μM cardamonin (Tocris Bioscience, Bristol, UK) for 30 min [25] (link) and then incubated with or without HTNV for different times.

Yu H., Jiang W., Du H., Xing Y., Bai G., Zhang Y., Li Y., Jiang H., Zhang Y., Wang J., Wang P, & Bai X. (2014). Involvement of the Akt/NF-κB Pathways in the HTNV-Mediated Increase of IL-6, CCL5, ICAM-1, and VCAM-1 in HUVECs. PLoS ONE, 9(4), e93810.

+ Open protocol

+ Expand

Evaluating NF-κB Modulators in Cell Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

NF-κB antagonist and agonists: TNFα (315–01A, Peprotech, Rocky Hill, NJ, USA ), Prostratin (5739, Tocris, Bristol, UK), CGS 21680 HCl (1063, Tocris), Betulinic acid (53603, Selleck Chemicals, Houston, TX, USA), PSI (4045, Tocris), Cardamonin (2509, Tocris), Bay 11–7082 (S2913, Selleck Chemicals), Bay 11–7085 (S7352, Selleck Chemicals), RO 106–9920 (1778, Tocris), TPCA-1 (S2824, Selleck Chemicals), Ikk-16 (S2882, Selleck Chemicals), PF 184 (4238, Tocris), IMD 0354 (2483, Tocris), Andrographolide (S2261, Selleck Chemicals), Costunolide (2483, Tocris), CID 2858522 (4246, Tocris), Pictilisib (S1065, Selleck Chemicals), Luteolin (S2320, Selleck Chemicals), Celastrol (1571, Tocris), Artemisinin (2668, Tocris). Cells were plated (at a seeding density of 1x10⁴ for 96 well plates and 1x10³ for 384 well plates) 12 h before treatment. Cells were treated with drugs at a range of concentrations either with fresh media (for agonists and vehicle only control) or fresh media with 5ng/ml TNFα (for antagonists and vehicle control) and incubated for 24 h. Each drug dose was performed in triplicate or quadruplicate and experiments were repeated at least three times.

Harrold A.P., Cleary M.M., Bharathy N., Lathara M., Berlow N.E., Foreman N.K., Donson A.M., Amani V., Zuercher W.J, & Keller C. (2020). In vitro benchmarking of NF-κB inhibitors. European journal of pharmacology, 873, 172981.

+ Open protocol

+ Expand

Culturing Breast Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

SUM190 and SUM149 were obtained from Asterand (Detroit, MI, USA) and cultured in Hams F-12 media (Mediatech, Manassas, VA, USA) containing 5 μg/ml insulin, 1 μg/ml hydrocortisone, antibiotics (penicillin/streptomycin), and 5% (SUM149) or 2% (SUM190) of fetal bovine serum (FBS) (HyClone, Logan, UT, USA). Medium for SUM190 cells was further supplemented with 5 mM ethanolamine, 10 mM HEPES, 5 μg/ml transferrin, 6.6 ng/ml 3,3',5-triiodo-L-thyronine sodium salt, 8.7 ng/ml sodium selenite, and 1 mg/ml bovine serum albumin (BSA). Cells were cultured at 37 °C in a 5% CO₂ incubator. Breast cancer cell lines BT483 and Cama-1 were purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained in DMEM-F12 (1:1) supplemented with 10% FBS. Poly(I:C) was obtained from InvivoGen (San Diego, CA, USA). Doxorubicin hydrochloride, 5-Fluorouracil, Paclitaxel, insulin, hydrocortisone, HEPES, and BSA were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cardamonin and Bay 11-7821 were purchased from TOCRIS Bioscience (Ellisville, MO, USA).

Jia D., Yang W., Li L., Liu H., Tan Y., Ooi S., Chi L., Filion L.G., Figeys D, & Wang L. (2014). β-Catenin and NF-κB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer. Cell Death and Differentiation, 22(2), 298-310.

+ Open protocol

+ Expand

Culturing Breast Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Breast cancer cell line SUM190 were obtained from Asterand (Detroit, MI, USA) and cultured in Hams F-12 media (Mediatech, Manassas, VA, USA) containing 5 μg/ml insulin, 1 μg/ml hydrocortisone, antibiotics (penicillin/streptomycin), and 2% of fetal bovine serum (HyClone, Logan, UT, USA). Medium for SUM190 cell culture was further supplemented with 5 mM ethanolamine, 10 mM HEPES, 5 μg/ml transferrin, 6.6 ng/ml 3,3′,5-triiodo-L-thyronine sodium salt, 8.7 ng/ml sodium selenite, and 1 mg/ml bovine serum albumin. Cells were cultured at 37°C in a 5% CO2 incubator. Breast cancer cell lines MCF-7, MDA-AB-231 and Cama-1 were purchased from the American Type Culture Collection (Manassas, VA) and maintained in DMEM-F12 (1:1) supplemented with 10% fetal bovine serum (FBS). Doxorubicin hydrochloride, 5-fluorouracil, paclitaxel, insulin, hydrocortisone, HEPES, and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cardamonin was purchased from TOCRIS bioscience (Ellisville, MO, USA). B27 supplement was purchased from Fisher (Cat. 17504-044), and EGF and bFGF from RD (Cat. 236-EG-200 and 234-FSE).

Jia D., Tan Y., Liu H., Ooi S., Li L., Wright K., Bennett S., Addison C.L, & Wang L. (2015). Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo. Oncotarget, 7(1), 771-785.

+ Open protocol

+ Expand

Oxazolone-induced Oxidative Stress in HaCaT Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Oxazolone was purchased from Sigma-Aldrich (St. Louis, MO, USA). Cardamonin was purchased from TOCRIS bioscience (Bristol, UK). Dulbecco’s modified Eagle’s medium (DMEM), heat-inactivated fetal bovine serum (FBS), phosphate-buffered saline (PBS), and penicillin/streptomycin (Pen/Strep) were purchased from Welgene (Daegu, Korea). Polyclonal antibodies against NRF2 were purchased from Cell Signaling Technology (Danvers, MA, USA). Monoclonal antibodies against total actin and 8-hydroxydeoxyguanosine (8-OH-dG) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Polyclonal antibodies against 4-hydroxynonenal (4-HNE) were purchased from Abcam (Cambridge, MA, USA). Human keratinocyte HaCaT cells were acquired from American Type Culture Collection (Manassas, VA, USA).

Yoo O.K., Choi W.J, & Keum Y.S. (2020). Cardamonin Inhibits Oxazolone-Induced Atopic Dermatitis by the Induction of NRF2 and the Inhibition of Th2 Cytokine Production. Antioxidants, 9(9), 834.

+ Open protocol

+ Expand

Antagonists and Agonists of Prostaglandin E Receptors

Check if the same lab product or an alternative is used in the 5 most similar protocols

EP1 antagonist (SC-51089), EP2 agonist (Butaprost), EP2 antagonist (TG4-155), EP4 agonist (CAY10598), EP4 antagonists (GW627368X, L-161, 982), and prostaglandin E₂ were from Cayman Chemical (Ann Arbor, MI). EP3 antagonist (L798, 106) and cardamonin were obtained from Tocris (Minneapolis, MN). IKK inhibitor III was from Millipore Sigma (Burlington, MA). Tri-reagent was obtained from Molecular Research Center (Cincinnati, OH). All other drugs were obtained from Sigma Aldrich.

Bryson T.D., Ross J., Peterson E, & Harding P. (2019). Prostaglandin E2 and an EP4 Receptor Agonist Inhibit LPS-Induced Monocyte Chemotactic Protein 5 Production and Secretion in Mouse Cardiac Fibroblasts via Akt and NF-κB Signaling.. Prostaglandins & other lipid mediators, 144, 106349.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!